Medicaid Coverage for Ozempic, Wegovy & Mounjaro: Weight Loss Drugs Explained
Maryland’s Republican lawmakers are pushing for a $449 million increase to the state’s Medicaid budget, a move that would expand coverage to include weight-loss drugs like Ozempic and Wegovy, despite existing budgetary concerns. The proposal comes as states across the country grapple with the rising costs and coverage questions surrounding glucagon-like peptide-1 (GLP-1) receptor agonists.
The Maryland GOP’s plan directly addresses the increasing demand for these medications, often touted by physicians as effective treatments for obesity and related health conditions. Though, the move is occurring at a time when many states are re-evaluating their Medicaid policies regarding GLP-1 drugs, with some restricting coverage to specific diagnoses or limiting the duration of treatment. Pennsylvania, for example, will stop covering the medications for weight loss next month, according to reporting from 90.5 WESA.
The debate centers on the high cost of these drugs – Ozempic, Wegovy, and Mounjaro are all GLP-1 receptor agonists – and questions about their appropriate use. While doctors have described Ozempic as a “miracle drug,” Medicaid officials are expressing reservations, as reported by Politico. Concerns include the potential for off-label prescriptions, the long-term effects of the medications, and the financial strain on state budgets.
Currently, Medicaid generally covers GLP-1 drugs only when prescribed for diagnosed diabetes. Expanding coverage to include weight loss, even for individuals with obesity, represents a significant policy shift and a substantial financial commitment. The Maryland proposal seeks to broaden that coverage, but faces scrutiny given the state’s overall fiscal situation.
Recent reporting from Penn LDI highlights growing barriers to access for patients seeking these medications, even with insurance coverage. These barriers include prior authorization requirements, step therapy protocols, and limitations on the quantity of medication dispensed. The Maryland proposal, if enacted, would potentially alleviate some of these access issues for Medicaid recipients within the state.
The Maryland legislature is scheduled to continue debate on the budget proposal, with a final vote expected in the coming weeks. The outcome will likely set a precedent for other states considering similar expansions of Medicaid coverage for GLP-1 drugs.